BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1147 related articles for article (PubMed ID: 9423798)

  • 1. Selective screening for the Factor V Leiden mutation: is it advisable prior to the prescription of oral contraceptives?
    Schambeck CM; Schwender S; Haubitz I; Geisen UE; Grossmann RE; Keller F
    Thromb Haemost; 1997 Dec; 78(6):1480-3. PubMed ID: 9423798
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk of venous thrombosis in carriers of the prothrombin G20210A variant and factor V Leiden and their interaction with oral contraceptives.
    Aznar J; Vayá A; Estellés A; Mira Y; Seguí R; Villa P; Ferrando F; Falcó C; Corella D; España F
    Haematologica; 2000 Dec; 85(12):1271-6. PubMed ID: 11114134
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Resistance to activated protein C in women using oral contraceptives.
    Spannagl M; Dick A; Assmann A; Heinemann L; Schramm W
    Semin Thromb Hemost; 1998; 24(5):423-30. PubMed ID: 9834008
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The Bavarian Thromboembolic Risk Cohort Study (BATER). Study protocol, state of the investigation and first results].
    Schramm W; Heinemann LA; Spannagl M; Dick A; Assmann A
    Dtsch Med Wochenschr; 2000 Jan; 125(1-2):2-6. PubMed ID: 10650817
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined effect of factor V Leiden and prothrombin 20210A on the risk of venous thromboembolism--pooled analysis of 8 case-control studies including 2310 cases and 3204 controls. Study Group for Pooled-Analysis in Venous Thromboembolism.
    Emmerich J; Rosendaal FR; Cattaneo M; Margaglione M; De Stefano V; Cumming T; Arruda V; Hillarp A; Reny JL
    Thromb Haemost; 2001 Sep; 86(3):809-16. PubMed ID: 11583312
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thrombotic risk factors and oral contraception.
    Bokarewa MI; Falk G; Sten-Linder M; Egberg N; Blombäck M; Bremme K
    J Lab Clin Med; 1995 Sep; 126(3):294-8. PubMed ID: 7665978
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The relationship of the factor V Leiden mutation and pregnancy outcomes for mother and fetus.
    Dizon-Townson D; Miller C; Sibai B; Spong CY; Thom E; Wendel G; Wenstrom K; Samuels P; Cotroneo MA; Moawad A; Sorokin Y; Meis P; Miodovnik M; O'Sullivan MJ; Conway D; Wapner RJ; Gabbe SG;
    Obstet Gynecol; 2005 Sep; 106(3):517-24. PubMed ID: 16135581
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of Factor V Leiden and prothrombin G20210-->A mutations on thromboembolic risk in the national surgical adjuvant breast and bowel project breast cancer prevention trial.
    Abramson N; Costantino JP; Garber JE; Berliner N; Wickerham DL; Wolmark N
    J Natl Cancer Inst; 2006 Jul; 98(13):904-10. PubMed ID: 16818854
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Factor V Leiden (Arg506Gln), a confounding genetic risk factor but not mandatory for the occurrence of venous thromboembolism in homozygotes and obligate heterozygotes for cystathionine beta-synthase deficiency.
    Yap S; O'Donnell KA; O'Neill C; Mayne PD; Thornton P; Naughten E
    Thromb Haemost; 1999 Apr; 81(4):502-5. PubMed ID: 10235428
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen.
    Bloemenkamp KW; Rosendaal FR; Helmerhorst FM; Büller HR; Vandenbroucke JP
    Lancet; 1995 Dec; 346(8990):1593-6. PubMed ID: 7500751
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Can a change in screening and prescribing practice reduce the risk of venous thromboembolism in women taking the combined oral contraceptive pill?
    Mills A; Wilkinson C; Fotherby K
    Br J Fam Plann; 1998 Jan; 23(4):112-5. PubMed ID: 9882763
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Venous thrombotic risk in family members of unselected individuals with factor V Leiden.
    Lensen RP; Bertina RM; de Ronde H; Vandenbroucke JP; Rosendaal FR
    Thromb Haemost; 2000 Jun; 83(6):817-21. PubMed ID: 10896231
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Probability of recurrence of thrombosis in patients with and without factor V Leiden.
    Rintelen C; Pabinger I; Knöbl P; Lechner K; Mannhalter C
    Thromb Haemost; 1996 Feb; 75(2):229-32. PubMed ID: 8815565
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk of thrombosis associated with oral contraceptives of women from 97 families with inherited thrombophilia: high risk of thrombosis in carriers of the G20210A mutation of the prothrombin gene.
    Santamaría A; Mateo J; Oliver A; Menéndez B; Souto JC; Borrell M; Soria JM; Tirado I; Fontcuberta J
    Haematologica; 2001 Sep; 86(9):965-71. PubMed ID: 11532625
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Activated protein C resistance and venous thrombophilia: molecular genetic prevalence study in the German population].
    Ehrenforth S; Klinke S; von Depka Prondzinski M; Kreuz W; Ganser A; Scharrer I
    Dtsch Med Wochenschr; 1999 Jun; 124(25-26):783-7. PubMed ID: 10414227
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Should female relatives of factor V Leiden carriers be screened prior to oral contraceptive use? A cost-effectiveness analysis.
    Smith KJ; Monsef BS; Ragni MV
    Thromb Haemost; 2008 Sep; 100(3):447-52. PubMed ID: 18766261
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High risk of cerebral-vein thrombosis in carriers of a prothrombin-gene mutation and in users of oral contraceptives.
    Martinelli I; Sacchi E; Landi G; Taioli E; Duca F; Mannucci PM
    N Engl J Med; 1998 Jun; 338(25):1793-7. PubMed ID: 9632445
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The emotional impact of genetic testing and aspects of counseling prior to prescription of oral contraceptives.
    Gartner V; Weber M; Eichinger S
    Contraception; 2008 Nov; 78(5):392-8. PubMed ID: 18929736
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Contribution of prothrombin 20210A allele and factor V Leiden mutation to thrombosis risk in thrombophilic families with other hemostatic deficiencies.
    Tirado I; Mateo J; Soria JM; Oliver A; Borrell M; Coll I; Vallvé C; Souto JC; Martínez-Sánchez E; Fontcuberta J
    Haematologica; 2001 Nov; 86(11):1200-8. PubMed ID: 11694407
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The influence of thrombotic risk factors when oral contraceptives are prescribed. A control-only study.
    Lidegaard O
    Acta Obstet Gynecol Scand; 1997 Mar; 76(3):252-60. PubMed ID: 9093141
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 58.